Jim Mullen scours private equity deals amid biotech winter; Ex-AbbVie medical chief succeeds Briggs Morrison at Syndax
Jim Mullen is in, by his count, his third or fourth “long, cold winter in biotech investing.” But that’s not stopping the ex-Biogen CEO from finding flickers of light.
Earlier this week, private equity player Advent International announced that Mullen had joined as an operating partner — its term for independent advisors who bring industry experience.
Mullen told Endpoints News in an interview that he’s been doing advising work for a number of private equity firms and enjoyed it.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters